XORTX Therapeutics Inc (XRTX)
NASDAQ:XRTX
XRTX Stock Chart & Stats
$0.58
-$0.02(-1.68%)
At close: 4:00 PM EST
$0.58
-$0.02(-1.68%)
Day’s Range― - ―
52-Week Range$1.73 - $7.05
Previous CloseN/A
Volume19.17K
Average Volume (3M)3.79M
Market Cap
$3.18M
Enterprise Value$402.49K
Total Cash (Recent Filing)$250.45K
Total Debt (Recent Filing)$15.07K
Price to Earnings (P/E)―
Beta0.47
Next Earnings
Aug 13, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-10.94
Shares Outstanding1,392,444
10 Day Avg. Volume11,302,330
30 Day Avg. Volume3,791,937
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)1.75
Price to Sales (P/S)0.00
P/FCF Ratio-1.29
Enterprise Value/Market Cap0.13
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-4.79
Enterprise Value/Ebitda-0.19
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-1.26
Revenue Forecast (FY)$2.33M
Bulls Say, Bears Say
Bulls Say
Focused Clinical-stage Pipeline In Kidney DiseaseA clear, focused R&D strategy centered on uric-acid control for kidney disorders creates a durable value proposition: it concentrates resources on a defined unmet clinical need, improves trial design coherence, and enhances attractiveness to partners or acquirers if clinical endpoints are met.
Very Low Financial LeverageMinimal debt materially reduces bankruptcy and liquidity risk, giving management flexibility to prioritize R&D or negotiate partnerships without heavy interest burdens. Low leverage preserves optionality during clinical development and is a durable financial strength over months.
Meaningful Improvement In Operating Loss TrajectoryA sustained reduction in operating losses signals improving cost discipline and more efficient development spending. This trend lowers future funding needs, extends runway, and indicates management can stabilize operations—an important durable improvement for a development biotech.
Bears Say
No Revenue And Continued Net LossesAs a clinical-stage company with no product revenue, XORTX remains entirely reliant on external financing or partnerships. Persistent net losses mean long-term sustainability depends on successful trials or capital raises, raising dilution and execution risk over the next several months.
Persistent Negative Operating And Free Cash FlowConsistently negative operating and free cash flows show the company cannot self-fund development today. Although burn has improved, ongoing outflows necessitate financing or partnering, which can be dilutive or constrain strategic choices—an enduring structural weakness.
Material Decline In Equity Base And Thin Capital CushionA sharply reduced equity base reflects cumulative losses and past dilution, leaving a thinner buffer against shocks. That weaker capital cushion increases the likelihood and frequency of future external raises, limiting negotiating leverage and raising medium-term solvency risk.
XORTX Therapeutics Inc News
XRTX FAQ
What was XORTX Therapeutics Inc’s price range in the past 12 months?
XORTX Therapeutics Inc lowest stock price was $1.73 and its highest was $7.05 in the past 12 months.
What is XORTX Therapeutics Inc’s market cap?
XORTX Therapeutics Inc’s market cap is $3.18M.
When is XORTX Therapeutics Inc’s upcoming earnings report date?
XORTX Therapeutics Inc’s upcoming earnings report date is Aug 13, 2026 which is in 70 days.
How were XORTX Therapeutics Inc’s earnings last quarter?
XORTX Therapeutics Inc released its earnings results on May 16, 2026. The company reported -$0.58 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.58.
Is XORTX Therapeutics Inc overvalued?
According to Wall Street analysts XORTX Therapeutics Inc’s price is currently Overvalued.
Does XORTX Therapeutics Inc pay dividends?
XORTX Therapeutics Inc pays a Quarterly dividend of $0.075 which represents an annual dividend yield of N/A. See more information on XORTX Therapeutics Inc dividends here
What is XORTX Therapeutics Inc’s EPS estimate?
XORTX Therapeutics Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does XORTX Therapeutics Inc have?
XORTX Therapeutics Inc has 1,392,444 shares outstanding.
What happened to XORTX Therapeutics Inc’s price movement after its last earnings report?
XORTX Therapeutics Inc reported an EPS of -$0.58 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -9.686%.
Which hedge fund is a major shareholder of XORTX Therapeutics Inc?
Currently, no hedge funds are holding shares in XRTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
XORTX Therapeutics Inc
XORTX Therapeutics Inc., a bio-pharmaceutical company, engages in the development and commercialization of therapies to treat progressive kidney diseases, diabetes, insulin resistance, metabolic syndrome, diabetes, diabetic nephropathy, and infection. It develops XRx-008, a late clinical stage program therapy for autosomal dominant polycystic kidney disease; XRx-101, an uric acid lowering agent used to treat patients infected with the coronavirus COVID-19 infection and suppression of acute kidney injury and associated health consequences; and XRx-221, a xanthine oxidase inhibitor candidates for the treatment of diabetic nephropathy. The company has a partnership with the Icahn School of Medicine to study the incidence of acute kidney injury and hyperuricemia in patients hospitalized with COVID-19. XORTX Therapeutics Inc. is based in Vancouver, Canada.
Technical Analysis
Aptose Biosciences
―
Kane Biotech
―
Quest Pharmatech
―
BioVaxys Technology
―
Doseology Sciences
―
Ownership Overview
9.10%
Insiders
1.08% Other Institutional Investors
89.82% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---